TRK inhibitors have been approved for the treatment of TRK fusion cancers, and approximately 40% of patients with PDAC who cannot produce serine after surgery may be treated with a combination of TRK inhibitors and a low-serine diet to reduce cancer recurrence. The gene discussed is NTRK1; the disease is cancer.